bearish
M3: Covid Related Trials and Vaccination Programs Drive Earnings; Core Business Growth Slowing Down
214 Views03 Feb 2022 02:51
m3's 3QFY03/2022 earnings were driven by Covid-related clinical trials and vaccination projects that will come to an end once pandemic ease off. Core business is slowing down and m3 has announced...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Lepu Biopharma IPO: PHIP Updates09 Feb 2022
- MicroPort NeuroTech IPO: Impressive Product Portfolio Offsets Profitability Concerns07 Feb 2022
- Takeda: Key Drugs Continue Growth and Upgrade to Guidance; Pipeline Progress Despite Recent Setbacks03 Feb 2022
- M3: Covid Related Trials and Vaccination Programs Drive Earnings; Core Business Growth Slowing Down03 Feb 2022
- Hoya: Life Care Exceeds Pre-Covid Levels; Slight Upgrade to Forecasts with a Small Buyback01 Feb 2022
- M3: Share Price Heading into a Correction and Further 20-25% Downside Likely22 Dec 2021
- M3: Strong 2Q Results but Earnings Growth Starts Decelerating28 Oct 2021
x